Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, will be participating in the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, will be participating in the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022. The presentation, featuring CEO Taylor Schreiber and CFO Andrew Neill, will take place on April 11 at 1:30 p.m. ET. This virtual conference aims to highlight Shattuck's innovative bi-functional fusion proteins designed to treat cancer and autoimmune diseases, with ongoing Phase 1 clinical trials for products like SL-172154 and SL-279252. A live webcast will be available on the company's website.
Positive
- Participation in a prestigious healthcare conference could enhance visibility and investor interest.
- Ongoing Phase 1 clinical trials indicate active research and development in innovative treatment options.
Negative
- None.
Details
News Market Reaction – STTK
The recorded move for STTK in the trading session of this news was -2.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 21st Annual Needham Virtual Healthcare Conference being held April 11-14, 2022.
Presentation Details
Conference: 21st Annual Needham Virtual Healthcare Conference
Format: Fireside chat with covering analyst Gil Blum, Ph.D.
Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, M.B.A., Shattuck’s Chief Financial Officer
Date: April 11, 2022
Time: 1:30 p.m. ET
A live webcast of the presentation will be available on the Events & Presentations section of the Company’s website. A replay of the webcasts will be archived for up to 90 days following the presentation date.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, with multiple ongoing Phase 1 clinical trials. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.shattucklabs.com.
Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.